MD
MDMXF.US medmix AG
- Market cap
- USD 726M
- P/E
- 1,740.0x
- P/B
- 1.37x
- ROE
- 1.5%
- Dividend yield
- 3.15%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is MDMXF.US undervalued?
Graham numberThe Graham number of medmix AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
medmix AG fundamental analysis
No fundamental analysis for medmix AG yet.
medmix AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About medmix AG
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, …
Full company profilemedmix AG financial statements
medmix AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 351M | 457M | 477M | 487M | 484M | 448M |
| Gross Profit | 121M | 181M | 175M | 158M | 160M | 162M |
| Operating Income | 20.4M | 62.9M | 49.5M | 14.2M | 18.1M | 27.8M |
| EBITDA | - | - | 69.7M | 71.4M | 67.3M | 75.2M |
| Net Income | 9.60M | 44.0M | 11.6M | 300K | -7.40M | 6.40M |
| EPS | 0.23 | 1.07 | 0.28 | 0.01 | -0.18 | 0.16 |
| Balance Sheet | ||||||
| Total Assets | 792M | 974M | 1.11B | 1.01B | 954M | 956M |
| Total Liabilities | 459M | 441M | 601M | 532M | 508M | 524M |
| Shareholders' Equity | 333M | 534M | 505M | 474M | 436M | 433M |
| Cash & Short-term Investments | 14.8M | 210M | 314M | 131M | 96.2M | 82.1M |
| Cash Flow | ||||||
| Operating Cash Flow | 50.6M | 87.3M | 47.6M | 56.1M | 86.6M | 67.8M |
| Capital Expenditure | 43.1M | 31.9M | 38.6M | 52.9M | 48.5M | 41.1M |
| Free Cash Flow | 7.50M | 55.4M | 9.00M | 3.20M | 38.1M | 26.7M |
| Ratios | ||||||
| ROE | 2.9% | 8.2% | 2.3% | 0.1% | -1.7% | 1.5% |
| ROA | 1.2% | 4.5% | 1.0% | 0.0% | -0.8% | 0.7% |
| Net Profit Margin | 2.7% | 9.6% | 2.4% | 0.1% | -1.5% | 1.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
medmix AG dividends
- Dividend yield
- 3.15%
- Forward dividend
- 0.55 USD
- Payout ratio
- 234.4%
- Ex-dividend date
- Apr 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 15.0M | 0.37 | 234.4% |
| 2024 | CHF 15.0M | 0.37 | - |
| 2023 | CHF 15.0M | 0.37 | 5,000.0% |
| 2022 | CHF 15.0M | 0.37 | 129.3% |
| 2021 | CHF 41.3M | 1.00 | 93.9% |
| 2020 | CHF 52.0M | 1.26 | 541.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns medmix AG
- Insiders 44.21%
- Institutions 18.55%
- Public & others 37.25%
- Shares outstanding 41.7M
- Free float 39.3M
medmix AG company profile
- Company name
- medmix AG
- Ticker
- MDMXF.US
- Exchange
- USA Stocks
- Sector
- Industrials
- Industry
- Specialty Industrial Machinery
- Employees
- 2,587
- Fiscal year end
- December
- Address
- Neuhofstrasse 20, Baar, Switzerland, 6340
- Phone
- 41 41 723 7300
- Website
- medmix.swiss
About medmix AG
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.
medmix AG management
10- Dr. Rene Willi Ph.D.Chief Executive Officer · born 1967
- Mr. Sven LuginbuehlGroup Chief Financial Officer
- Dr. Andreas Friis-HansenChief Operating Officer
- Mr. Francisco FaoroChief Technology Officer
- Mr. Domenico TruncellitoHead of Corporate Communications & Investor Relations
- Mr. Jasper Den OudenChief Human Resources & Sustainability Officer · born 1975
- Ms. Jennifer DeanHead of Beauty Business Unit · born 1968
- Ms. Ayse SanliogluHead of Business Unit Dental
- Mr. Roman ThoenigHead of Business Segment Industry
- Ms. Kara ZweizigHead of Business Segment Surgery